16257-05-9

Basic information

• Product Name: BOC-ILE-GLY-OH
• Synonyms: BOC-ILE-GLY-OH;N-T-boc-ile-gly;N-(tert-butoxycarbonyl)-Ile-Gly;N-[N-(tert-Butoxycarbonyl)-L-isoleucyl]glycine;Boc-Ile-Gly
• CAS NO: 16257-05-9
• Molecular Formula: C₁₃H₂₄N₂O₅
• Molecular Weight: 288.34
• Mol File: 16257-05-9.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 499.6±30.0 °C(Predicted)
• Appearance: /
• Density: 1.122±0.06 g/cm3(Predicted)
• Storage Temp.: -15°C
• PKA: 3.42±0.10(Predicted)
• CAS DataBase Reference: BOC-ILE-GLY-OH(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-ILE-GLY-OH(16257-05-9)
• EPA Substance Registry System: BOC-ILE-GLY-OH(16257-05-9)

Safety Data

• Hazardous Substances Data: 16257-05-9(Hazardous Substances Data)

Upstream product

• 56439-59-9 2-((2S,3S)-2-((tert-butoxycarbonyl)amino)-3-methylpentanamido)acetic aid ethyl ester 
• 13139-16-7 N-(tert-butyloxycarbonyl)-L-isoleucine 
• 3392-08-3 N-(tert-butoxy)carbonyl-L-isoleucine N-hydroxysuccinimide ester 
• 56-40-6 glycine 
• 16257-04-8 BOC-Ile-Gly-OMe 

Downstream Products

• 1071814-98-6 Boc-Ile-Gly-N-Me-D-Phe-Pro-OM 
• 16257-06-0 tert.-Butyloxycarbonyl-Ile-Gly-(p-nitro-phenylester) 

Relevant articles and documents

Catch and Release Photosensitizers: Combining Dual-Action Ruthenium Complexes with Protease Inactivation for Targeting Invasive Cancers

Dual action agents containing a cysteine protease inhibitor and Ru-based photosensitizer for photodynamic therapy (PDT) were designed, synthesized, and validated in 2D culture and 3D functional imaging assays of triple-negative human breast cancer (TNBC). These combination agents deliver and release Ru-based PDT agents to tumor cells and cause cancer cell death upon irradiation with visible light, while at the same time inactivating cathespin B (CTSB), a cysteine protease strongly associated with invasive and metastatic behavior. In total five Ru-based complexes were synthesized with the formula [Ru(bpy)2(1)](O2CCF3)2 (3), where bpy = 2,2′-bipyridine and 1 = a bipyridine-based epoxysuccinyl inhibitor; [Ru(tpy)(NN)(2)](PF6)2, where tpy = terpiridine, 2 = a pyridine-based epoxysuccinyl inhibitor and NN = 2,2′-bipyridine (4); 6,6′-dimethyl-2,2′-bipyridine (5); benzo[i]dipyrido[3,2-a:2′,3′-c]phenazine (6); and 3,6-dimethylbenzo[i]dipyrido[3,2-a:2′,3′-c]phenazine (7). Compound 3 contains a [Ru(bpy)3]2+ fluorophore and was designed to track the subcellular localization of the conjugates, whereas compounds 4-7 were designed to undergo either photoactivated ligand dissociation and/or singlet oxygen generation. Photochemical studies confirmed that complexes 5 and 7 undergo photoactivated ligand dissociation, whereas 6 and 7 generate singlet oxygen. Inhibitors 1-7 all potently and irreversibly inhibit CTSB. Compounds 4-7 were evaluated against MDA-MB-231 TNBC and MCF-10A breast epithelial cells in 2D and 3D culture for effects on proteolysis and cell viability under dark and light conditions. Collectively, these data reveal that 4-7 potently inhibit dye-quenched (DQ) collagen degradation, whereas only compound 7 causes efficient cell death under light conditions, consistent with its ability to release a Ru(II)-based photosensitizer and to also generate 1O2.

Proline compounds as Granzyme B inhibitors

Proline compounds as Granzyme B inhibitors, compositions that include the compounds, and methods for using the compounds. Methods for treating cutaneous scleroderma, epidermolysis bullosa, radiation dermatitis, alopecia areata, and discoid lupus erythematosus are provided.

Synthesis of the eledoisin-(4-11)-octapeptides lys-asp(NH2)-ala-phe-ile-gly-leu-met-NH2 and their heterologs with hydrazine acetic acid instead of glycine

-